NAD+ and the Science of Cellular Longevity
NAD+ declines roughly 50% by age 40. Here's what that means for your mitochondria, your DNA repair, and your energy — and how supplementation changes the equation.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell. It serves two fundamental roles: it is the primary electron carrier in cellular energy metabolism, and it is the essential substrate for sirtuins and PARP enzymes — proteins that govern DNA repair, stress response, and gene expression. Without adequate NAD+, cells age faster.
The Decline Problem
NAD+ levels fall approximately 50% between age 20 and 40, and continue declining thereafter. The causes are multifactorial: increased CD38 activity (an enzyme that degrades NAD+), decreased biosynthesis, and chronic inflammation — which consumes NAD+ via PARP activation. The result is measurably impaired mitochondrial function, reduced DNA repair capacity, and disrupted circadian signaling.
NMN, NR, and the Precursor Question
The two most studied NAD+ precursors are NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside). Both raise NAD+ levels in human trials. NMN has demonstrated efficacy at 250–1200 mg/day, with a 2021 study by Yoshino et al. showing significant increases in skeletal muscle NAD+ and improvements in insulin sensitivity in prediabetic women. IV NAD+ infusions raise systemic levels most rapidly — often used as a loading protocol.
Practical Implications for Longevity Protocols
NAD+ optimization is increasingly viewed as foundational to longevity medicine — not as a standalone intervention but as part of a stack that may include mTOR inhibition, senolytics, and mitochondrial support. At 877PEPTIDE, longevity protocols are physician-supervised and lab-monitored, ensuring the intervention matches your baseline and goals.